Of all the reasons that customers purchase health insurance, the risk of cancer is very often the primary driver. And for most health funds around the world, cancer is the most significant claims line, if not by cost, then for its emotional significance.

Starting in Boston, MA, iFHP’s first study tour of 2024 will take members to the heart of the future developments in cancer therapies, exploring in detail what they mean to payers. From the latest in cancer genomics to precision therapies, immunotherapies, epigenetics, prevention and early detection, the tour will bring you to the cross roads where future cancer science and real-world funding meet.

We’ll explore the commercial aspects too. Participants will meet experts in novel payment models, including pricing and cost-effectiveness calculations developed specifically for oncology treatments. There will also be sessions on how AI is shaping the future of oncology and the new service models it will enable, plus what improvements we’re seeing in end-of-life strategies. The study tour finishes in New York, NY where we will join a full day of panel discussions with oncology experts from academia, industry, payers and providers from all over the United States.

This study tour is unique in its clear-eyed focus on the impact of the development of the advanced oncology systems of the future on the payer. And there’s no greater way to connect with peers over how payers worldwide are meeting the challenges of the future of oncology. We look forward to seeing you there!